Kremers Urban Is Fighting the FDA To Keep Its ADHD Drug on the Market
An FDA hearing will decide if one company can keep selling its generic extended-release methylphenidate tablets, which could affect availability and prices.
By Foodie Pundit Newsroom - Published - Updated - Section: Policy Regulation
Key points
- The FDA has granted Kremers Urban a hearing over its proposal to withdraw approval for their generic methylphenidate drug.
- The outcome of the hearing will determine if Kremers Urban can continue to sell its ADHD medication.
- This case highlights the FDA's role in ensuring generic drugs are therapeutically equivalent to their brand-name counterparts.
This report is part of Foodie Pundit premium coverage. Foodie Pundit members read the full story. See membership.
More from the Foodie Pundit Newsroom
- Your organic food is about to get a rules check
- India's organic soy tariffs: Your tofu price could shift.
- New York Michelin Guide Release Triggers Reservation Crunch And Economic Shift For Local Restaurants
- Why Girl Dinner Has Evolved From Social Media Meme to Grocery Sector Catalyst
- Restaurant Closures Surge Across Nation As Economic Pressures Mount